Status:
NOT_YET_RECRUITING
Dapagliflozin in Mangement of Pulmonary Hypertension Patients
Lead Sponsor:
Assiut University
Conditions:
Pulmonary Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Effect of SGLT2 (Dapagliflozin)on prognosis of patient with pulmonary Hypertension and Effect on RV function By speckle tract echocardiography at Assiut University Hospital.
Detailed Description
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and may be associated with a variety of cardiovascular and respiratory diseases. It is clinic...
Eligibility Criteria
Inclusion
- that the patients were diagnosed with pulmonary hypertension By Right heart cath OR suspected By Echocardiograghy according to the ESC guidelines for pulmonary hypertension that they were aged 18 years or older
Exclusion
- symptomatic hypotension (systolic blood pressure \< 95 mmHg)
- impaired renal function (eGFR \< 30 mL/min/1.73 m2 calculated according to the CKD-EPI formula) and serum potassium level \> 5.2 mmol/L
- hepatic dysfunction (defined as liver parameters such as ALT, AST, and/or ALP, which are three times above the upper 99-th percentile of the reference range
- biliary cirrhosis and cholestasis, active malignancies (regardless of the stage and type of malignancy)),
- the current use of hormone replacement therapy, chemotherapy, or immunotherapy
- Type 1 diabetes mellitus
- Acute pulmonary embolism (15)
- Signficant Primary valvular Heart disease
- Ischemic heart disease
Key Trial Info
Start Date :
October 25 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 10 2026
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06612086
Start Date
October 25 2024
End Date
October 10 2026
Last Update
October 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut university
Asyut, Egypt